文献速递消化系统肿瘤

转移性结直肠癌患者三线化疗再挑战的疗效:一项真实世界研究

[The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2023-01-01

该回顾性研究纳入2013年1月至2020年12月天津医科大学肿瘤医院95例经奥沙利铂和(或)伊立替康化疗后进展、三线接受化疗再挑战的mCRC患者,分析疗效与预后因素。客观缓解率8.6%(8/93),疾病控制率61.3%(57/93),中位无进展生存4.9个月,中位总生存13.0个月。多因素分析显示性别(HR=1.609,95%CI:1.016~2.548)及一线+二线PFS(HR=0.598,95%CI:0.378~0.947)是独立影响因素。

要点

  • 三线化疗再挑战客观缓解率8.6%(8/93),疾病控制率61.3%(57/93)。
  • 中位无进展生存4.9个月,中位总生存13.0个月。
  • 性别(HR=1.609,95%CI:1.016~2.548)及一线+二线PFS(HR=0.598,95%CI:0.378~0.947)为独立影响因素。

核心结论

  • 作者认为mCRC患者三线治疗采用化疗再挑战安全有效,尤其是一线治疗和二线治疗PFS累计超过1年者,三线治疗选择化疗再挑战的疗效可能更优。

研究设计与样本

  • 回顾性研究,纳入2013年1月至2020年12月天津医科大学肿瘤医院经奥沙利铂和(或)伊立替康化疗后进展且三线接受化疗再挑战的mCRC患者95例。
  • 采用Kaplan-Meier法进行生存分析,采用Cox比例风险模型分析预后影响因素。

主要发现

  • 95例患者中,三线治疗采用单纯化疗32例(33.7%),化疗联合靶向治疗63例(66.3%)。
  • 83例(87.4%)采用双药化疗,其中奥沙利铂再挑战35例,伊立替康再挑战48例;12例(12.6%)采用三药化疗。
  • 三药化疗的12例中,5例因前线序贯应用奥沙利铂和伊立替康,三线为奥沙利铂和伊立替康再挑战;7例前线仅使用过奥沙利铂,归于奥沙利铂再挑战。
  • 客观缓解率8.6%(8/93),疾病控制率61.3%(57/93),中位无进展生存4.9个月,中位总生存13.0个月。
  • 常见不良反应为白细胞减少(34.7%)、中性粒细胞减少(34.7%)、恶心(32.6%)、呕吐(31.6%),3~4级不良反应多见于骨髓抑制;多因素Cox回归显示性别(HR=1.609,95%CI:1.016~2.548)及一线治疗的PFS+二线治疗的PFS(HR=0.598,95%CI:0.378~0.947)是独立影响因素。

关键数值与推荐

  • 客观缓解率8.6%(8/93),疾病控制率61.3%(57/93)。
  • 中位无进展生存4.9个月,中位总生存13.0个月。
  • 性别HR=1.609(95%CI:1.016~2.548);一线治疗的PFS+二线治疗的PFS HR=0.598(95%CI:0.378~0.947)。

临床怎么用

  • 原文结论为mCRC患者三线治疗采用化疗再挑战安全有效,尤其是一线治疗和二线治疗PFS累计超过1年者,三线治疗选择化疗再挑战的疗效可能更优。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the efficacy of chemotherapy re-challenge in the third-line setting for patients with metastatic colorectal cancer (mCRC) in the real world. Methods: The clinicopathological data, treatment information, recent treatment efficacy, adverse events and survival data of mCRC patients who had disease progression after treatment with oxaliplatin-based and/or irinotecan-based chemotherapy and received third-line chemotherapy re-challenge from January 2013 to December 2020 at Tianjin Medical University Cancer Institute and Hospital were retrospectively collected. Survival curves were plotted with the Kaplan-Meier method, and the Cox proportional hazard model was used to analyze the prognostic factors. Results: A total of 95 mCRC patients were included. Among them, 32 patients (33.7%) received chemotherapy alone and 63 patients (66.3%) received chemotherapy combined with targeted drugs. Eighty-three patients were treated with dual-drug chemotherapy (87.4%), including oxaliplatin re-challenge in 35 patients and irinotecan re-challenge in 48 patients. The remaining 12 patients were treated with triplet chemotherapy regimens (12.6%). Among them, as 5 patients had sequential application of oxaliplatin and irinotecan in front-line treatments, their third-line therapy re-challenged both oxaliplatin and irinotecan; 7 patients only had oxaliplatin prescription before, and these patients re-challenged oxaliplatin in the third-line treatment. The overall response rate (ORR) and disease control rate (DCR) reached 8.6% (8/93) and 61.3% (57/93), respectively. The median progression free survival (mPFS) and median overall survival (mOS) were 4.9 months and 13.0 months, respectively. The most common adverse events were leukopenia (34.7%) and neutropenia (34.7%), followed by gastrointestinal adverse reactions such as nausea (32.6%) and vomiting (31.6%). Grade 3-4 adverse events were mostly hematological toxicity. Cox multivariate analysis showed that gender (HR=1.609, 95% CI: 1.016-2.548) and the PFS of front-line treatments (HR=0.598, 95% CI: 0.378-0.947) were independent prognostic factors. Conclusion: The results suggested that it is safe and effective for mCRC patients to choose third-line chemotherapy re-challenge, especially for patients with a PFS of more than one year in front-line treatments. 目的: 评价真实世界中转移性结直肠癌(mCRC)患者三线化疗再挑战的临床疗效。 方法: 2013年1月至2020年12月于天津医科大学肿瘤医院经奥沙利铂和(或)伊立替康化疗后进展且三线接受化疗再挑战的mCRC患者95例,收集其临床病理资料、治疗相关信息、近期疗效、不良反应及生存资料。采用Kaplan-Meier法进行生存分析,采用Cox比例风险模型分析mCRC患者三线化疗再挑战的预后影响因素。 结果: 95例患者中,三线治疗采用单纯化疗32例,化疗联合靶向治疗63例。83例患者采用双药化疗,其中35例为奥沙利铂再挑战,48例为伊立替康再挑战。12例(12.6%)患者采用三药化疗,其中5例因前线序贯应用奥沙利铂和伊立替康,三线治疗为奥沙利铂和伊立替康再挑战,7例前线仅使用过奥沙利铂,归于奥沙利铂再挑战。三线化疗再挑战的客观缓解率为8.6%(8/93),疾病控制率为61.3%(57/93),中位无进展生存时间(PFS)为4.9个月,中位总生存时间为13.0个月。常见的不良反应为白细胞减少(34.7%)、中性粒细胞减少(34.7%),以及恶心(32.6%)、呕吐(31.6%)等消化道不良反应。3~4级不良反应多见于骨髓抑制。多因素Cox回归分析显示,性别(HR=1.609,95% CI:1.016~2.548)、一线治疗的PFS+二线治疗的PFS(HR=0.598,95% CI:0.378~0.947)是mCRC患者三线化疗再挑战PFS的独立影响因素。 结论: mCRC患者三线治疗采用化疗再挑战安全有效,尤其是一线治疗和二线治疗PFS累计超过1年者,三线治疗选择化疗再挑战的疗效可能更优。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Duan JJ, Ning T, Bai M, et al. [The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study]. Zhonghua Zhong Liu Za Zhi. 2023. PMID: 37968083. doi:10.3760/cma.j.cn112152-20220901-00591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。